Member Info for Energyshares

Encouraging to highly encouraging …..

Billy Tap you tease.

Dr. Coughlin will provide strategic leadership for the recently launched biotech and its clinical-stage pipeline of engineered NK cell therapies designed to improve outcomes for patients with cancer. Dr. Coughlin will join the company’s Board of Directors.

Dr. Coughlin joins CytoImmune from Rubius Therapeutics, Inc. where she served as the Chief Medical Officer and led the clinical development, translational medicine, and regulatory efforts in the allogeneic red cell therapy platform. Prior to Rubius, Dr. Coughlin was with Tmunity Therapeutics, Inc., where she served as Chief Medical Officer and was responsible for the preclinical and clinical development of autologous CAR-T and TCR-T cellular therapies. Dr. Coughlin has held other leadership roles in the pharmaceutical and biotechnology fields in her career including Chief Medical Officer at Immunocore, heading the development of the soluble TCR platform, and Oncology Asset Team Leader at Pfizer.

Plenty of experience as a CMO Avacta have a plan we find out tomorrow .

GLA

DTW

Most cardiotoxicity caused by

Drug to drug inter-actions

AVA6000 doesn’t have this problem.

As with most cancer treatments doxorubicin is rarely given in isolation. Most of the in-vivo studies involve cotreatment with other antineoplastic agents such as taxanes, platinum drugs, nitrogen mustard analogs, fluoropyrimidines, and vinca alkaloids, which can complicate the association of variants with a particular treatment.

More clinically relevant are the drug–drug interactions resulting in the cardiotoxicity from cotreatment with doxorubicin and trastuzumab or taxanes such as paclitaxel and docetaxel .

No one has done it:

Finding a way to maintain the efficacy and reduce toxicity has been one of the major areas of focus of anthracycline research.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116111/

Wednesday 13th December 2023

One company has done it….

GLA

Wednesday is like Christmas Day for all of BP.

They have had their present early with Avacta telling them they have chemo without side effects which is a new paradigm shift in oncology.

But Wednesday they finally get to open the present with full instructions available.

Everyone needs to read the instructions to work out how best to use your new present.

GLA

Shaun has held a number of senior and executive commercial positions over more than 30 years in companies in pharmaceutical and pharmaceutical services industries. These include at Pfizer, Sanofi, Wolters Kluwer Health and KnowledgePoint360 Group (now part of UDG Healthcare).

Dr Eliot Forster, Chairman of the Board of Avacta Group plc commented:

"Along with my fellow Directors I am delighted to welcome Shaun to the Board of Avacta Group. He brings a wide range of highly relevant commercial experiences from successful healthcare businesses with similar ambitions for growth that we have in Avacta. I know Shaun will positively impact our shared thinking and I'm excited to have him join the company."

Dr Alastair Smith, Chief Executive of Avacta Group plc commented:

"I am delighted that Shaun has joined the Board of Avacta Group. He brings deep and extensive commercial experience to further strengthen the senior leadership of the Group as it executes its strategy across two divisions to build a major global healthcare business working to improve people's health and well-being through innovative oncology drugs and powerful diagnostics."

Shaun Chilton, Non-Executive Director of Avacta Group, commented:

"Avacta Group is building a high value, global business that is seeking to significantly improve people's health and well-being. I am excited to leverage my own broad experience of growing healthcare businesses and working with the other members of the Board to help guide Avacta to meet its very significant potential."

LSE have took my capital letters away 😂

looking back over this year you can see from the rns’s it was the 5th cohort were they started to see remarkable results.

shaun chilton was appointed just a couple of days before they announced the end of cohort 5.

what have they seen ?

for them to appoint a well connected proven executive of a disruptive venture capital backed medical technology and services business….

a new paradigm shift in oncology…

a disruptive way to treat cancer…

we find out next week,but you can bet shaun chilton won’t be scratching is **** after he has had access to the data.

funding….he has the backing and respect of venture capitalist and the connections to the top table of the biggest pharma companies in the world.

alongside his role as the ceo of clinigen, shaun was non-executive chairman of c7health, a disruptive, venture capital-backed medical technology and services business which executed an acquisitive growth journey before successfully being acquired by a strategic buyer in 2022. 

then avacta have some of the top oncologist in the world working with them, not bad for a little biotech on aim.

after the completion of fifth dose the rns’s dried up for nearly 3 months and avacta changed direction with phase 1b and data readout.

what has happened ?

i’m expecting avacta to blow the bloody doors off next week.

gla

Avacta have done one deal for its Pre/Cision platform.

Remember this deal was done just five months after 1st patient was dosed for AVA6000. Now they are in such a stronger position after 848 days data.

Let’s say we use the last agreement as a template (which wont happen)

The agreement provides POINT with an exclusive license to the pre|CISION technology for use in the first radiopharmaceutical prodrug the company intends to develop, and a non-exclusive license to the pre|CISION™ platform for the development of a broader pipeline of FAP-activated radiopharmaceuticals.

Under the terms of the agreement, Avacta will receive an upfront fee and development milestones for the first radiopharmaceutical prodrug totalling $9.5 million. Avacta will also receive milestone payments for subsequent radiopharmaceutical prodrugs of up to $8 million each, a royalty on sales of FAP-activated radiopharmaceuticals by POINT and a percentage of any sublicensing income received by POINT.

So they gave them 1 prodrug exclusive and non- exclusive for subsequent

radiopharmaceutical prodrugs.

Let’s say Novartis take AVA3996 exclusive licence and give them non- exclusive for any of their own drugs to use Pre/Cision

Then another Big Pharma take the next one of Avacta’s Pre/Cision pipeline with same deal.

The scramble would be on for all the other Big Pharma to grab one of Avacta’s Pre/Cision pipeline and get the same deal.

We could end up owning AVA6000 with a Large Pharma as a partner , and every drug in Avacta pipeline being pushed through development,ASAP

Think of the Licence fees ££££

Think of the milestone payments ££££

Think of the Royalties ££££

Think of the sublicensing income ££££

Just on the Pre/Cision pipeline.

Now think of Think of the milestone payments ££££

Think of the Royalties ££££

Think of the sublicensing income ££££ of all the other drugs these Big Pharma go on to adopt Pre/Cision with their own toxic chemo’s.

Wow,Wow,Wow

GLA………..

So Point or Ely Lilly only have an exclusive licence for the first Canseek drug it develops.

Then any others are non-exclusive.

This opens the door for others like Novartis & Sofie to licence Radioligand Pre/Cision drugs.

Great deal by the Avacta board.

The agreement provides POINT with an exclusive license to the pre|CISION technology for use in the first radiopharmaceutical prodrug the company intends to develop, and a non-exclusive license to the pre|CISION™ platform for the development of a broader pipeline of FAP-activated radiopharmaceuticals.

Under the terms of the agreement, Avacta will receive an upfront fee and development milestones for the first radiopharmaceutical prodrug totalling $9.5 million. Avacta will also receive milestone payments for subsequent radiopharmaceutical prodrugs of up to $8 million each, a royalty on sales of FAP-activated radiopharmaceuticals by POINT and a percentage of any sublicensing income received by POINT.

We all know it’s radiotherapy but if data blows the doors off it helps Can seek trial

Has the Eli Lilly board just made a $Million dollar mistake hours after Avacta announces 13th December PK data release.

Point Bio shareholders must be rubbing their hands, they get to see Avacta PK data two days before Dec 15th deadline for accepting Ely Lilly offer.

They have the only Pre/Cision licence so far with Can-seek, if Avacta reveal another licence agreement with the data it could cost Eli Lilly a lot more than $12.50.

Dec 4 (Reuters) - Eli Lilly (LLY.N) on Monday again extended its deadline for Point Biopharma Global (PNT.O) shareholders to sell their shares to the drugmaker, following low participation amid investor concerns that the offer price was low.

Lilly set Dec. 15 as the deadline in a third extension. The Indianapolis-based drugmaker maintained its offer price at $12.50 per share, which is over 10% lower than Point Biopharma's last closing price of $13.80.

message to m&m’s

a clinical stage oncology drug innovator will be releasing pk data in 7 working days time.

do your best,but my shares are staying in my **** pocket.

i don’t think anyone even heights will let go until then so where is your market.

A clinical stage oncology drug innovator

Meeting is 12 days to Christmas and Avacta gave PK data to me….

When AVA6000 displaces dox as first line treatment for STS,

As well as side effect free it will also save a lot of hassle in the administration of the drug.

Read this article from a nurse who administers the drug.

https://voice.ons.org/news-and-views/outpatient-oncology-drug-series-doxorubicin-is-the-infamous-red-devil

AVA6000 could be Paradigm shift in oncology that Avacta keeps telling us.

GLA

Look at this company privately owned Dracen Pharmaceuticals very similar to Avacta as they are using a prodrug to kill tumours with reduced side effects.

Sep 2020 entered into Phase 1 first in human trials,just a month later Oct 2020 received fast track approval from FDA.

Then 4 months later signed a deal with Merck the collaboration was for their pro drug to work with Keytruda,

just shows you how many of Big Pharma will come knocking for their chemo drugs to have their side effects removed and patents extended.

I said the other day we could receive Fast track before phase 2 but a few disagreed,

if Dracen Pharma can do it why can’t Avacta.

Hold on to your hats

GLA

https://www.dracenpharma.com/dracen-pharmaceuticals-announces-the-initiation-of-first-in-human-study-of-drp-104-in-adult-patients-with-advanced-solid-tumors/

https://www.dracenpharma.com/dracen-pharmaceuticals-drp-104-granted-u-s-fda-fast-track-designation-for-the-treatment-of-non-small-cell-lung-cancer/

http://www.dracenpharma.com/wp-content/uploads/2021/03/17775654PreviewRelease.pdf

https://www.dracenpharma.com/#ne

If it starts leaking on Ava6000 success in clinics in USA.

What can a patient do if they didn’t qualify for AVA6000 trial.

In America they have the Right to try in law.

Come on Avacta let’s get this platform on the media news.

https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/right-try

What is FDA expanded access program?

Sometimes called “compassionate use”, expanded access is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials.

What is the FDA approval rate for expanded access?

approximately 99%

FDA have a webinar on EAP

Join us for a free CE webinar on December 12, 2023 from 1 to 2 PM ET to learn about the FDA’s Project Facilitate Oncology Expanded Access Program. Register today :

Look where it’s from…..

I wonder …..

FDA Drug Topics: An Overview of FDA’s Project Facilitate Oncology Expanded Access Program

Date & Time

Dec 12, 2023 06:00 PM 

in London.

https://fda.zoomgov.com/webinar/register/WN_65SY0ANjSNmnDJ3sd8OODg?utm_medium=email&utm_source=govdelivery#/registration

This tough year for biotech has been marked by investors having zero patience for any time horizons longer than maybe a quarter or two. ImmunoGen was hammered ~3 months ago when the CMO left because “obviously a sale wasn’t imminent.” Bad move for weak hands today.

@bradloncar “x”twitter

I can see this playing out with Avacta

No patience some investors

Stupid trolls and greedy traders…..

Chemo without side effects:

A new paradigm in cancer drug development:

British Avacta Therapeutics is a pioneer of next-generation cancer therapies:

Full Story

Coming to all media channels

Very soon.

GLA